A Phase 2 Study of Balstilimab Independently or in Combination With Zalifrelimab in Cervical Cancer
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy
,safety and pharmacokinetics of Balstilimab (Treatment Arm 1 - monotherapy) or in combination
with Zalifrelimab (Treatment Arm 2- combination therapy) for treatment of patients with
advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based
chemotherapy.